Reply

Journal of the American College of Cardiology

Volumn 55, Issue 9, 2010, Pages 931-932

  Poulter, Neil R ^a   Dobson, Joanna E ^a   Sever, Peter S ^a   Dahlöf, Björn ^a   Campbell, Norm R C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; TRANDOLAPRIL PLUS VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; HEART RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LETTER; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 76849111902     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.11.038     Document Type: Letter

References (5)

1. Poulter N.R., Dobson J.E., Sever P.S., et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 54 (2009) 1154-1161
2. Hansen T.W., Thijs L., Boggia J., et al. Prognostic value of ambulatory heart rate revisited in 6928 subjects from 6 populations. Hypertension 52 (2008) 229-235
3. Bangalore S., Sawhney S., Messerli F.H., et al. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 52 (2008) 1482-1489
4. Kolloch R., Legler U.F., Champion A., et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 29 (2008) 1327-1334
5. Poulter N.R., Wedel H., Dahlöf B., et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366 (2005) 907-913